Details for New Drug Application (NDA): 213878
NDA 213878 describes CABOZANTINIB S-MALATE, which is a drug marketed by MSN and is included in one NDA. Additional details are available on the CABOZANTINIB S-MALATE profile page.
The generic ingredient in CABOZANTINIB S-MALATE is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
The generic ingredient in CABOZANTINIB S-MALATE is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
Summary for 213878
| Tradename: | CABOZANTINIB S-MALATE |
| Applicant: | Msn |
| Ingredient: | cabozantinib s-malate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Aug 14, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 40MG BASE | ||||
| Approval Date: | Aug 14, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 60MG BASE | ||||
| Approval Date: | Aug 14, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
